Jeremy Schafer

A look into the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.

The rapid pace of new pharmaceutical approvals raises questions of whether ICER can keep up and maintain the quality and rigor demanded by healthcare audiences, writes Jeremy Schafer.

Strategies for pharma in delivering the full picture to patients.

Pharmaceutical manufacturers should plan for a DTC strategy to minimize the risk of patient abandonment due to pricing concerns.

Charting the course that has led to payer vertical integration and what it may mean for pharma manufacturers.